Skip to main content Accessibility help
×
Home

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

  • S. Charles Schulz (a1), Mary C. Zanarini (a2), Anthony Bateman (a3), Martin Bohus (a4), Holland C. Detke (a5), Quynh Trzaskoma (a5), Yoko Tanaka (a5), Daniel Lin (a5), Walter Deberdt (a6) and Sara Corya (a5)...

Abstract

Background

Despite the prevalence and clinical significance of borderline personality disorder, its treatment remains understudied.

Aims

To evaluate treatment with variably dosed olanzapine in individuals with borderline personality disorder.

Method

In this 12-week randomised, double-blind trial, individuals received olanzapine (2.5–20 mg/day; n=155) or placebo (n=159) (trial registry: NCT00091650). The primary efficacy measure was baseline to end-point change on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN–BPD) using last-observation-carried-forward methodology.

Results

Both olanzapine and placebo groups showed significant improvements but did not differ in magnitude at end-point (76.56 v. 76.25, P=0.661). Response rates (50% reduction in ZAN–BPD) were 64.7% with olanzapine and 53.5% with placebo (P=0.062); however, time to response was significantly shorter for olanzapine (P=0.022). Weight gain was significantly greater (2.86 v. 70.35 kg, P50.001), with higher incidence of treatment-emergent abnormal high levels of prolactin for the olanzapine group.

Conclusions

Individuals treated with olanzapine and placebo showed significant but not statistically different improvements on overall symptoms of borderline personality disorder. The types of adverse events observed with olanzapine treatment appeared similar to those observed previously in adult populations.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
      Available formats
      ×

Copyright

Corresponding author

Dr S. Charles Schulz, Department of Psychiatry, Medical School, F282/2A West, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. Email: scs@umn.edu

Footnotes

Hide All

Declaration of interest

This study was sponsored by Eli Lilly. S.C.S. has received honorarium from Eli Lilly, AstraZeneca and Bristol-Meyers Squibb; grant fees from Eli Lilly, AstraZeneca, Abbott, MIND Institute and the NIMH; and consultation fees from Eli Lilly, AstraZeneca and Vanda. H.C.D., Q.T., Y.T., D.L. and S.C. are employed by Lilly Research Laboratories.

Footnotes

References

Hide All
1 Swartz, M, Blazer, D, George, L, Winfield, I. Estimating the prevalence of borderline personality disorder in the community. J Personal Disord 1990; 4: 257–72.
2 Torgersen, S, Kringlen, E, Cramer, V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001; 58: 590–6.
3 Skodol, AE, Gunderson, JG, McGlashan, TH, Dyck, IR, Stout, RL, Bender, DS, Grilo, CM, Shea, MT, Zanarini, MC, Morey, LC, Sanislow, CA, Oldham, JM. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive–compulsive personality disorder. Am J Psychiatry 2002; 159: 276–83.
4 Stone, MH. Long-term outcome in personality disorders. Br J Psychiatry 1993; 162: 299313.
5 Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103–7.
6 Bogenschutz, MP, George, NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104–9.
7 Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402–5.
8 Nickel, MK, Muehlbacher, M, Nickel, C, Kettler, C, Pedrosa, GF, Bachler, E, Buschmann, W, Rother, N, Fartacck, R, Egger, C, Anvar, J, Rother, WK, Loew, TH, Kaplan, P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833–8.
9 Rocca, P, Marchiaro, L, Cocuzza, E, Bogetto, F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241–4.
10 Soler, J, Pascual, JC, Campins, J, Barrachina, J, Puigdemont, D, Alvarez, E, Perez, V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221–4.
11 Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849–54.
12 Zanarini, MC, Frankenburg, FR, Parachini, EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903–7.
13 Zanarini, MC, Schulz, SC, Detke, HC, Tanaka, Y, Zhao, F, Lin, D, DeBerdt, W, Corya, S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2006; 9 (suppl 1): s191.
14 Frankenburg, FR, Zanarini, MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442–6.
15 Soloff, PH, Lynch, KG, Kelly, TM, Malone, KM, Mann, JJ. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study. Am J Psychiatry 2000; 157: 601–8.
16 Zanarini, MC, Vujanovic, AA, Parachini, EA, Boulanger, JL, Frankenburg, FR, Hennen, J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN–BPD): a continuous measure of DSM–IV borderline psychopathology. J Personal Disord 2003; 17: 233–42.
17 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
18 First, MB, Gibbon, M, Spitzer, RL, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Research Version, Patient Edition (SCID–I/P). Biometrics Research, New York State Psychiatric Institute, 2001.
19 Derogatis, LR, Savitz, KL. The SCL–90–R, brief symptom inventory and matching clinical rating scales. In The Use of Psychological Testing for Treatment Planning and Outcome Assessment (ed. Maruish, ME): 4180. Lawrence Erlbaum Associates, 1999.
20 American Psychiatric Association. Global Assessment of Functioning (GAF) Scale. In Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR): 32–4. APA, 2000.
21 Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11 (suppl 3): 8995.
22 Coccaro, EF, Harvey, PD, Kupsaw-Lawrence, E, Herbert, JL, Bernstein, DP. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991; 3: s44S51.
23 Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
24 Davidson, J, Turnbull, CD, Strickland, R, Miller, R, Graves, K. The Montgomery–Åsberg depression rating scale: reliability and validity. Acta Psychiatr Scand 1986; 73: 544–8.
25 National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.
26 American Diabetic Assocation. Standards of medical care in diabetes. Diabetes Care 2004; 27 (suppl 1): s1535.
27 Simpson, EB, Yen, S, Costello, E, Rosen, K, Begin, A, Pistorello, J, Pearlstein, T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 379–85.
28 Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6.
29 Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare, 1976.
30 Schulz, SC, Camlin, KL, Berry, SA, Jesberger, JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429–35.
31 Khan, A, Kolts, RL, Rapaport, MH, Krishnan, KR, Brodhead, AE, Browns, WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med 2005; 5: 743–9.
32 Walsh, BT, Seidman, SN, Sysko, R, Gould, M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840–7.
33 Goldberg, SC, Schulz, SC, Schulz, PM, Resnick, RJ, Hamer, RM, Friedel, RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680–6.
34 Tohen, M, Sanger, TM, McElroy, SL, Tollefson, GD, Chengappa, KN, Daniel, DG, Petty, F, Centorrino, F, Wang, R, Grundy, SL, Greaney, MG, Jacobs, TG, David, SR, Toma, V. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156: 702–9.
35 Tohen, M, Jacobs, TG, Grundy, SL, Banov, MC, McElroy, SL, Janicak, PG, Sanger, T, Risser, R, Zhang, F, Toma, V, Francis, J, Tollefson, GD, Breier, A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841–9.
36 Soloff, PH, George, A, Nathan, RS, Schulz, PM, Ulrich, RF, Perel, JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691–7.
37 Cowdry, RW, Gardner, DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111–9.
38 Cornelius, JR, Soloff, PH, Perel, JM, Ulrich, RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991; 11: 116–20.
39 Markovitz, PJ, Calabrese, JR, Schulz, SC, Meltzer, HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064–7.
40 Coccaro, EF, Kavoussi, RJ. Fluoxetine and impulsive aggressive behavior in personality–disordered subjects. Arch Gen Psychiatry 1997; 54: 1081–8.
41 Salzman, C, Wolfson, AN, Schatzberg, A, Looper, J, Henke, R, Albanese, M, Schwartz, J, Miyawaki, E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23–9.
42 Markovitz, PJ, Wagner, SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31: 773–7.
43 Hollander, E, Tracy, KA, Swann, AC, Coccaro, EF, McElroy, SL, Wozniak, P, Sommerville, KW, Nemeroff, CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacol 2003; 28: 1186–97.

Related content

Powered by UNSILO

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

  • S. Charles Schulz (a1), Mary C. Zanarini (a2), Anthony Bateman (a3), Martin Bohus (a4), Holland C. Detke (a5), Quynh Trzaskoma (a5), Yoko Tanaka (a5), Daniel Lin (a5), Walter Deberdt (a6) and Sara Corya (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

  • S. Charles Schulz (a1), Mary C. Zanarini (a2), Anthony Bateman (a3), Martin Bohus (a4), Holland C. Detke (a5), Quynh Trzaskoma (a5), Yoko Tanaka (a5), Daniel Lin (a5), Walter Deberdt (a6) and Sara Corya (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *